Cargando…

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated to asbestos exposure. One of the most frequent genetic alteration in MPM patients is CDKN2A/ARF loss, leading to aberrant activation of the Rb pathway. In MPM cells, we previously demonstrated the therapeutic eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonelli, Mara, Terenziani, Rita, Zoppi, Silvia, Fumarola, Claudia, La Monica, Silvia, Cretella, Daniele, Alfieri, Roberta, Cavazzoni, Andrea, Digiacomo, Graziana, Galetti, Maricla, Petronini, Pier Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403976/ https://www.ncbi.nlm.nih.gov/pubmed/32708306 http://dx.doi.org/10.3390/ijms21145165

Ejemplares similares

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
por: La Monica, Silvia, et al.
Publicado: (2019)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
por: Cavazzoni, Andrea, et al.
Publicado: (2017)

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
por: Fumarola, Claudia, et al.
Publicado: (2017)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
por: Cretella, Daniele, et al.
Publicado: (2019)

Hypertonic Stress and Amino Acid Deprivation Both Increase Expression of mRNA for Amino Acid Transport System A
por: Alfieri, Roberta R., et al.
Publicado: (2005)

Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review
por: Folesani, Giuseppina, et al.
Publicado: (2023)

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC
por: Adorni, Maria Pia, et al.
Publicado: (2023)

New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway
por: Alfieri, Roberta, et al.
Publicado: (2017)

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method
por: Bozzetti, Cecilia, et al.
Publicado: (2015)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Integrin α2 and β1 Cross-Communication with mTOR/AKT and the CDK-Cyclin Axis in Hepatocellular Carcinoma Cells
por: Juratli, Mazen A., et al.
Publicado: (2022)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report()()
por: Rihawi, Karim, et al.
Publicado: (2018)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
por: Kuramochi, Masami, et al.
Publicado: (2023)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt–mTOR and Cyclin–CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines
por: Rutz, Jochen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_16r5gfv8uquifgj197ppqtkajc